Genetic depletion of BAP1 or inhibition of BAP1 activity by small molecule inhibitors [18] could dramatically reduce the tumor growth of BAP1-dependent cancer, such as ASXL1-mutant leukemia [19], breast cancer [19], and SCLC [18]. Here, ASXL1 is linked to leukemia.